<table id="L132f9278-c9ec-4748-8702-8fbe4cf5db07" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><caption>TABLE 1 SUMMARY OF EFFECTIVENESS  DATA INPLACEBO-CONTROLLED TRIALS</caption>
<colgroup>
<col width="28%"></col>
<col width="8%"></col>
<col width="11%"></col>
<col width="14%"></col>
<col width="8%"></col>
<col width="14%"></col>
<col width="14%"></col>
</colgroup>
<thead>
<tr><td align="center"></td><td align="center"></td><td align="center" colspan="2">SYMPTOM SCORE<sup>a</sup></td><td align="center"></td><td align="center" colspan="2">MAXIMUM  FLOW  RATE (mL/sec)</td></tr>
<tr><td align="center"></td><td align="center"><br/><content stylecode="underline">N</content></td><td align="center">Mean<br/><content stylecode="underline">Baseline</content></td><td align="center">Mean<sup>b</sup><br/><content stylecode="underline">Change</content></td><td align="center"><br/><content stylecode="underline">N</content></td><td align="center">Mean <br/><content stylecode="underline">Baseline</content></td><td align="center">Mean<sup>c</sup><br/><content stylecode="underline">Change</content></td></tr>
</thead>
<tbody>
<tr><td>STUDY 1 (Titration to maximum dose of 8 mg)<sup>e</sup></td><td align="center"><br/></td><td align="center"></td><td align="center"></td><td align="center"></td><td align="center"></td><td align="center"></td></tr>
<tr><td>Placebo</td><td align="center">47</td><td align="center">15.6</td><td align="center">-2.3</td><td align="center">41</td><td align="center">9.7</td><td align="center">+0.7<br/></td></tr>
<tr><td>Doxazosin Mesylate</td><td align="center"><br/>49</td><td align="center"><br/>14.5</td><td align="center"><br/>-4.9**</td><td align="center"><br/>41</td><td align="center"><br/>9.8</td><td align="center"><br/>+2.9**</td></tr>
<tr><td><br/>STUDY 2 (titration to fixed dose 14 weeks)<sup>d</sup></td><td align="center"></td><td align="center"></td><td align="center"></td><td align="center"></td><td align="center"></td><td align="center"></td></tr>
<tr><td>
												Placebo</td><td align="center">37</td><td align="center">20.7</td><td align="center">-2.5</td><td align="center">30</td><td align="center">10.6</td><td align="center">+0.1</td></tr>
<tr><td>
											Doxazosin Mesylate 4 mg</td><td align="center"><br/>38</td><td align="center"><br/>21.2</td><td align="center"><br/>-5.0**</td><td align="center"><br/>32</td><td align="center"><br/>9.8</td><td align="center"><br/>+2.3*</td></tr>
<tr><td>
												Doxazosin Mesylate 8 mg <br/></td><td align="center"><br/>42</td><td align="center"><br/>19.9</td><td align="center"><br/>-4.2*</td><td align="center"><br/>36</td><td align="center"><br/>10.5</td><td align="center"><br/>+3.3**</td></tr>
<tr><td>STUDY 3 (Titration to fixed dose-12 weeks)</td><td align="center"></td><td align="center"></td><td align="center"></td><td align="center"></td><td align="center"><br/></td><td align="center"></td></tr>
<tr><td>Placebo</td><td align="center">47</td><td align="center">14.9</td><td align="center">-4.7</td><td align="center">44</td><td align="center">9.9</td><td align="center">+2.1</td></tr>
<tr><td>Doxazosin Mesylate 4 mg</td><td align="center"><br/>46</td><td align="center"><br/>16.6</td><td align="center"><br/>-6.1*</td><td align="center"><br/>46</td><td align="center"><br/>9.6</td><td align="center"><br/>+2.6</td></tr>
</tbody>
</table>